Second-generation human adenovirus (hAd5) targeting multiple tumor associated antigens (PSA, MUC-1, Brachyury) demonstrated safety, with no dose-limiting toxicities in patients with advanced prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback